{
  "claim_id": "claim_000",
  "claim": "Flublok is approved for adults 18 years and older",
  "document": "FlublokPI",
  "verification_stats": {
    "total_extracted": 3,
    "verified": 0,
    "rejected": 3,
    "verification_rate": 0.0
  },
  "verified_evidence": [],
  "rejected_evidence": [
    {
      "id": "comp_1",
      "quote": "Safety and effectiveness of Flublok have not been established in children 3 years to less than 18 years of age.",
      "reason": "Verification failed",
      "original_explanation": "This quote supports the claim by indicating that Flublok is not approved for use in individuals under 18 years old, implying that its approved use begins at age 18."
    },
    {
      "id": "comp_2",
      "quote": "Reactogenicity data from a small Phase 2 trial (Study 5) in adults 18 through 49 years of age, 153 of whom received Flublok 135 mcg, are not presented. However, subjects from Study 5 are included in the description of deaths and serious adverse events (SAEs).",
      "reason": "Verification failed",
      "original_explanation": "This quote demonstrates that clinical studies and safety data for Flublok specifically include adults starting at age 18, supporting its approval for this age group."
    },
    {
      "id": "comp_3",
      "quote": "In the U.S. during the 2007-2008 influenza season in adults 18 49 years of age (Study 1). (1) Study 1 enrolled and vaccinated 4648 healthy adults (mean age 32.5 years) randomized in a 1:1 ratio to receive a single dose of Flublok (n=2344) or saline placebo (n=2304).",
      "reason": "Verification failed",
      "original_explanation": "This quote provides evidence that Flublok was studied and administered to adults 18 years and older, supporting its approval for this age group."
    }
  ],
  "model_used": "o4-mini"
}